Literature DB >> 705691

Immunologic studies of antithrombin III heparin cofactor in the newborn.

W E Hathaway, L L Neumann, C A Borden, L J Jacobson.   

Abstract

Serial quantitative immunoelectrophoretic (IE) measurements of antithrombin III heparin cofactor (AT III) were made in groups of well and sick newborn infants classified by gestational age. Collection methods (venous vs. capillary) did not influence the results; serum IE measurements were comparable to AT III activity by a clotting method. AT III is gestational age-dependent, increasing from 28.7% of normal adult values at 28--32 weeks to 50.9% at 37--40 weeks, and shows a gradual increase to term infant levels (57.4%) by 3--4 weeks of age. Infants with the respiratory distress syndrome (RDS) show lower levels of AT III in the 33--36 week group, 22% vs. 44% and in the 37--40 week group, 33.6% vs. 50.9%, then prematures without RDS. Infants of 28--32 week gestational age had only slight differences, RDS = 24%, non-RDS = 28.7%. The lowest levels of AT III were seen in patients with RDS complicated by disseminated intravascular coagulation and those with necrotizing enterocolitis. Crossed IE on representative infants displayed a consistent pattern which was identical to adult controls except for appropriate decreases in the amplitude of the peaks. The thrombotic complications seen in the sick preterm infant may be related to the low levels of AT III.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 705691

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Antithrombin III Supplementation in a Premature Infant: Is There a Target Antithrombin Level?

Authors:  Ankit Shukla; Chi Braunreiter
Journal:  J Pediatr Pharmacol Ther       Date:  2021-11-10

2.  Low antithrombin III in neonatal shock: DIC or non-specific protein depletion?

Authors:  B K Schmidt; T Muraji; A Zipursky
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

3.  Low antithrombin III: accurate predictor of idiopathic respiratory distress syndrome in premature neonates.

Authors:  W van den Berg; C Breederveld; J W ten Cate; M Peters; J J Borm
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

Review 4.  Antithrombin for respiratory distress syndrome in preterm infants.

Authors:  D Bassler; D Millar; B Schmidt
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.

Authors:  Jacqueline G Gerhart; Fernando O Carreño; Matthew Shane Loop; Craig R Lee; Andrea N Edginton; Jaydeep Sinha; Karan R Kumar; Carl M Kirkpatrick; Christoph P Hornik; Daniel Gonzalez
Journal:  Clin Pharmacol Ther       Date:  2022-05-18       Impact factor: 6.903

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.